Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease of Solid Tumours By Ogkologos - July 21, 2025 144 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Coronavirus reports – Part 9: “I am very relieved but I... March 4, 2021 Sound Waves Can Target Lymph Nodes And Help Kill Breast Cancer... November 22, 2019 17 Old Fashioned Ways to Get Rid of Ants in Your... March 27, 2019 Discover and translate – a mantra to work by October 17, 2022 Load more HOT NEWS What’s Your Mantra? Exercising While Living With Peripheral Neuropathy: What People Diagnosed With Cancer... New Treatment Approach Could Help Prevent Recurrences of Some Bladder Cancers Her Mother Died of Breast Cancer When She Was Five. 16...
